Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1994 1
2010 3
2011 5
2012 12
2013 11
2014 10
2015 22
2016 18
2017 10
2018 10
2019 5
2020 5
2021 1
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 23391144

103 results

Results by year

Filters applied: . Clear all
Page 1
Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program.
Perrot A, Monjanel H, Bouabdallah R, Quittet P, Sarkozy C, Bernard M, Stamatoullas A, Borel C, Bouabdallah K, Nicolas-Virelizier E, Fournier M, Morschhauser F, Brice P; Lymphoma Study Association (LYSA). Perrot A, et al. Haematologica. 2016 Apr;101(4):466-73. doi: 10.3324/haematol.2015.134213. Epub 2016 Jan 14. Haematologica. 2016. PMID: 26768687 Free PMC article.
Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event.
Gandhi MD, Evens AM, Fenske TS, Hamlin P, Coiffier B, Engert A, Moskowitz AJ, Ghosh N, Petrich AM, Lomasney J, Chadburn A, Wood GS, Salva K, Nardone B, Trifilio SM, Raisch DW, West DP, Gordon LI, Winter JN. Gandhi MD, et al. Blood. 2014 May 1;123(18):2895-7. doi: 10.1182/blood-2014-03-561878. Blood. 2014. PMID: 24786458 Free PMC article. No abstract available.
Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP).
Pavone V, Mele A, Carlino D, Specchia G, Gaudio F, Perrone T, Mazza P, Palazzo G, Guarini A, Loseto G, Eleonora P, Cascavilla N, Scalzulli P, Melpignano A, Quintana G, Di Renzo N, Tarantini G, Capalbo S. Pavone V, et al. Ann Hematol. 2018 Oct;97(10):1817-1824. doi: 10.1007/s00277-018-3379-5. Epub 2018 Jul 27. Ann Hematol. 2018. PMID: 30054707
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Gianni AM, Carella A, Osmanov D, Bachanova V, Sweetenham J, Sureda A, Huebner D, Sievers EL, Chi A, Larsen EK, Hunder NN, Walewski J; AETHERA Study Group. Moskowitz CH, et al. Lancet. 2015 May 9;385(9980):1853-62. doi: 10.1016/S0140-6736(15)60165-9. Epub 2015 Mar 19. Lancet. 2015. PMID: 25796459 Clinical Trial.
The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Gravanis I, Tzogani K, van Hennik P, de Graeff P, Schmitt P, Mueller-Berghaus J, Salmonson T, Gisselbrecht C, Laane E, Bergmann L, Pignatti F. Gravanis I, et al. Oncologist. 2016 Jan;21(1):102-9. doi: 10.1634/theoncologist.2015-0276. Epub 2015 Nov 30. Oncologist. 2016. PMID: 26621039 Free PMC article.
Brentuximab vedotin: axonal microtubule's Apollyon.
Mariotto S, Ferrari S, Sorio M, Benedetti F, Tridente G, Cavallaro T, Gajofatto A, Monaco S. Mariotto S, et al. Blood Cancer J. 2015 Aug 28;5(8):e343. doi: 10.1038/bcj.2015.72. Blood Cancer J. 2015. PMID: 26314985 Free PMC article. No abstract available.
103 results